Personalized Medicine
Study links uneven PARP inhibitor exposure in ovarian tumors to lysosomal drug “reservoirs”
በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ
Researchers say they have identified a cellular mechanism that may help explain why PARP inhibitors can affect tumor cells unevenly: in lab-grown slices of human ovarian tumors, some of these drugs accumulated inside lysosomes, forming slow-release stores that created patchy drug distribution across tissue and even between neighboring cells. The findings were reported in a 2026 paper in Nature Communications.
The American College of Cardiology and American Heart Association have issued new guidelines on cholesterol screening and management, urging earlier testing and personalized risk assessments. The recommendations, presented on March 28 in New Orleans, emphasize lowering LDL cholesterol and incorporating genetic factors like lipoprotein(a). A new risk calculator aims to predict heart disease over longer periods.
በAI የተዘገበ እውነት ተፈትሸ
University of Missouri researchers report that a small antibody fragment targeting the EphA2 protein can be tagged with a radioactive marker to make EphA2-positive tumors stand out on PET scans in mouse experiments, a step they say could help match patients to EphA2-targeted therapies.
MIT researchers have invented a swallowable pill that signals when medication is taken, aiming to combat poor adherence rates among patients. The device uses a biodegradable antenna to transmit a wireless confirmation shortly after ingestion. This innovation could benefit high-risk groups like organ transplant recipients and those with chronic infections.
በAI የተዘገበ
Researchers in Dresden have discovered that the protein MCL1, known for helping cancer cells evade death, also regulates their energy production through the mTOR pathway. This dual role explains why drugs targeting MCL1 can fight tumors but sometimes harm the heart. The team has developed a dietary approach to mitigate this cardiotoxicity, paving the way for safer therapies.
Scientists have identified a genetic modifier that helps cells cope with the loss of frataxin, the protein at the core of Friedreich’s ataxia. By lowering activity of the FDX2 gene, experiments in worms, human cells, and mice showed that key energy‑producing processes can be restored, pointing to a potential new treatment strategy.
በAI የተዘገበ እውነት ተፈትሸ
In a recent open-access interview, Dr. Eric J. Nestler, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, looks back on nearly four decades of research into how stress and drugs reshape brain function. He highlights the transcription factor ΔFosB’s role in long-lasting behavioral change and argues that understanding natural resilience could shift mental health care toward strengthening protective mechanisms, not just correcting damage.
Mayo Clinic identifies rare MET gene mutation causing fatty liver disease
February 17, 2026 15:51New light-based sensor detects early cancer biomarkers in blood
February 14, 2026 19:48Global study highlights ‘hidden’ gut bacteria CAG-170 as a potential marker of health
February 11, 2026 21:47Texas A&M researchers build customizable living vessel-on-a-chip to mimic branching, aneurysms and stenosis
February 11, 2026 19:08Scientists uncover epigenetic map of immune cells shaped by life experiences
January 05, 2026 05:46MRI-derived brain network patterns linked to short-term response to Yueju Pill in depression pilot trial
January 04, 2026 04:10Study advocates personalized breast cancer screening over annual mammograms
December 21, 2025 05:00Spanish researchers develop open-source tool for cancer gene networks
December 16, 2025 10:04AI tool links genetic mutations to likely disease categories
December 14, 2025 09:41Natural compound may enhance chemotherapy for aggressive leukemia